Great News! The key part of the USPTO announcement IMO is that this grants exclusivity to AVNR for Zenvia through 2025. Things are moving along nicely toward the roll-out of this new blockbuster drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.